| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 3,425 | 2,990 | 3,065 | 3,562 |
| Investments | 10,980 | 16,279 | 18,516 | 12,876 |
| Accounts receivable, net | 4,133 | 5,200 | 4,526 | 3,493 |
| Inventory | 5,307 | 5,448 | 7,049 | 8,633 |
| Restricted investments | NaN | 10,266 | 10,266 | 11,000 |
| Prepaid expenses and other current assets | 4,864 | 5,203 | 5,378 | 3,098 |
| Restricted cash and investments | 10,266 | NaN | NaN | NaN |
| Total current assets | 38,975 | 45,386 | 48,800 | 42,662 |
| Restricted cash | NaN | 0 | 0 | 0 |
| Total property and equipment, gross | 42,621 | 43,047 | NaN | NaN |
| Less accumulated depreciation and amortization | 28,581 | 28,200 | NaN | NaN |
| Property and equipment, net | 14,040 | 14,847 | 16,172 | 17,264 |
| Operating lease right-of-use assets | 3,062 | 3,217 | 3,497 | 3,772 |
| Finance lease right-of-use assets | 3,044 | 3,095 | 3,146 | 3,198 |
| Intangible assets, net | 3,005 | 4,345 | 5,685 | 7,025 |
| Other long-term assets | 2,678 | 2,694 | 1,762 | 2,089 |
| Total assets | 64,804 | 73,584 | 79,062 | 76,010 |
| Accounts payable | 5,062 | 5,590 | 5,990 | 6,244 |
| Accrued expenses | 3,996 | 5,460 | 4,706 | 3,405 |
| Contract liabilities | 1,126 | 967 | 1,180 | 1,165 |
| Operating lease liability | 646 | 697 | 1,025 | 1,348 |
| Finance lease liability | 246 | 249 | 251 | 254 |
| Convertible debentures payable (at fair value) | 10,152 | 9,979 | 9,825 | 11,762 |
| Total current liabilities | 21,228 | 22,942 | 22,977 | 24,178 |
| Operating lease liability, net of current portion | 2,507 | 2,489 | 2,599 | 2,704 |
| Finance lease liability, net of current portion | 3,463 | 3,480 | 3,495 | 3,511 |
| Long-term contract liabilities | 143 | 249 | 192 | 243 |
| Total liabilities | 27,341 | 29,160 | 29,263 | 30,636 |
| Common stock, 0.0001 par value 400,000,000 shares authorized at march 31, 2026 and december 31, 2025 11,276,500 and 10,740,200 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 1 | 1 | 1 | NaN |
| Additional paid-in capital | 765,373 | 764,026 | 761,479 | 748,568 |
| Accumulated deficit | -727,923 | -719,620 | -711,687 | -703,184 |
| Accumulated other comprehensive income | 12 | 17 | 6 | -10 |
| Total stockholders equity | 37,463 | 44,424 | 49,799 | 45,374 |
| Total liabilities and stockholders equity | 64,804 | 73,584 | 79,062 | 76,010 |
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)